Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fluicell ABOSTO:FLUI -0.32%47 Debt-to-Equity is 0.12 as of Jun. 2026, which is 8% below its 10-year median of 0.13. GuruFocus rates OSTO:FLUI with a GF Score™ of 47/100 and a GF Value™ of kr77.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 964 Biotechnology companies, Fluicell AB ranks better than 56.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Fluicell AB's Debt-to-Equity or its related term are showing as below:
OSTO:FLUI'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.78
Current: 0.12
During the past 11 years, the highest Debt-to-Equity Ratio of Fluicell AB was 0.78. The lowest was 0.01. And the median was 0.13.
OSTO:FLUI's Debt-to-Equity is ranked better than 56.22% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs OSTO:FLUI: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Fluicell AB Debt-to-Equity Related Terms
Fluicell AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Fluicell AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Fluicell AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Fluicell AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a Debt-to-Equity of 0.12 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fluicell AB and its competitors. This is near median its historical median of 0.13. Over the past decade, Fluicell AB's Debt-to-Equity has ranged from 0.01 to 0.78. According to the industry distribution chart, Fluicell AB ranks #422 out of 964 companies in the Biotechnology industry, placing it in the top 43.8%.
Is Fluicell AB's Debt-to-Equity too high?
Fluicell AB's current Debt-to-Equity of 0.12 is near median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.78. The Biotechnology industry median Debt-to-Equity is 0.16. Fluicell AB's value of 0.12 is 22.6% below this industry median. Based on the distribution chart, Fluicell AB ranks #422 out of 964 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #422 out of 964 companies for Debt-to-Equity. This puts Fluicell AB in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Fluicell AB's value of 0.12 is 22.6% below this benchmark. Historically, Fluicell AB's own Debt-to-Equity has ranged from 0.01 to 0.78 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.16, Fluicell AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current Debt-to-Equity of 0.12 is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current Debt-to-Equity is 0.12, which is near median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Possible Value Trap. The stock's GF Value™ is kr77.29, compared to a current price of kr31.00 — trading 59.9% below its estimated fair value. The current Debt-to-Equity is 0.12, which is near median its 10-year median of 0.13 and 22.6% below the Biotechnology industry median of 0.16. Fluicell AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Debt-to-Equity is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr31.00 is trading 59.9% below its estimated GF Value™ of kr77.29.
GuruFocus considers Fluicell AB to be Possible Value Trap.
Key valuation signals for OSTO:FLUI:
Debt-to-Equity: 0.12 (near median its 10-year median of 0.13)
GF Value™: kr77.29 vs. price of kr31.00 (59.9% below fair value)
Industry Position: 22.6% below the Biotechnology median (#422 of 964)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company specializing in high-resolution 3D bioprinting and single-cell technology. Its proprietary Biopixlar platform enables precise, nozzle-based printing of living cells to create complex human tissue models. The company operates through two main areas: contract research services and product development. Its contract research division provides human tissue-based screening models for drug development, with a focus on cardiac safety and kidney disease, serving pharmaceutical and biotechnology companies. Its regenerative medicine efforts target type 1 diabetes, exploring cell-based therapies to restore insulin production. Fluicell generates revenue primarily by offering bioprinting services and tissue models to research partners and through sales of its Biopixlar instruments and related consumables. The company is headquartered in Sweden and serves customers in the global life science and pharmaceutical research market.
47GF Score
Get the complete analysis for OSTO:FLUI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
